Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine

 Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine

Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine

Shots:

  • The US FDA’s approval is based on five P-II & P-III studies assessing MenQuadfi vs licensed quadrivalent meningococcal in ~5000 people aged ≥2yrs. Four studies evaluated MenQuadfi in meningococcal-naïve person and the other study evaluated MenQuadfi in persons prior to immunized with a quadrivalent meningococcal vaccine
  • Meningococcal-naïve person showed 55.4%–97.2% vaccine induced response 30 days following vaccination with MenQuadfi while prior vaccinated group demonstrated 92.2%–98.2% immune response against each serogroup. The company is investigating the vaccine in ongoing P-III study in infants as young as 6wks. of age
  • The approval marks MenQuadfi as the only US FDA approved quadrivalent meningococcal vaccine indicated for person 2-56yrs. of age and older and is the only vaccine that uses tetanus toxoid as a protein carrier

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Trax Retail

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post